Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Phase 2 Not yet recruiting 60 enrolled TG Therapeutics, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by positive and negative syndrome scale (PANSS) total score in participants with schizophrenia.

Timeline

Start: 2026-07-06
Primary completion: 2028-12-01
Completion: 2029-03-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ublituximab	Monoclonal antibody	—	Intravenous

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Summary

Timeline

Drugs

Indications